Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
News provided by
Share this article
Share this article
NEW YORK, Feb. 3, 2021 /PRNewswire/ Longevity Acquisition Corporation (NASDAQ: LOAC) (the Company ), a publicly-traded special purpose acquisition company, announced today that on February 3, 2021, 4D pharma plc (AIM: DDDD) ( 4D pharma ), a pharmaceutical company leading the development of Live Biotherapeutic products ( LBPs ) - a novel class of drug derived from the microbiome, and a business combination target of LOAC, has announced progress on activities in its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518. 4D pharma has continued to make excellent progress with the MRx0518 development program on multiple fronts. We have generated additional safety and efficacy data, building on the positive data from both the monotherapy and KEYTRUDA combination studies last year. This clinical and devel
Thanks to earlier detection, gene testing, and new treatments, people with lung cancer are living longer, healthier lives. Deaths from the most common type of lung cancer fell by 6.3% every year from 2013 through 2016, according to a study published in August 2020.
If you’ve been diagnosed with lung cancer, it’s important to think about steps you can take in partnership with your doctor to manage your care and maintain a healthy lifestyle so you can live well for as long as possible. One type of tool that can help: mobile apps.
“Apps are like your own personal mini-medical record,” says Cedric “Jamie” Rutland, MD, a pulmonary and critical care doctor in California and a national spokesperson for the American Lung Association. “They can take all the information about you, your condition, your treatment, and other important topics and organize it in a way that’s easily accessible.”
E-Mail
BOSTON - A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors later years.
The guidelines, published online today in a paper in
JAMA Oncology, recommend discontinuing routine mammograms for survivors with a life expectancy under five years; considering stopping screening for those with a 5-10-year life expectancy; and continuing mammography for those whose life expectancy is greater than 10 years. The guidelines will be complemented by printed materials to help survivors gauge their risk of cancer recurring in the breast and weigh the potential benefits and drawbacks of mammography with their health care team.
For breast cancer patients, a new technique known as radiofrequency seed localization is now available at West Calcasieu Cameron Hospital to guide surgeons to the precise area to be removed.
Triplet Shows Promising Activity in Unresectable/Metastatic CRC medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.